Inactive Instrument

COSMO Pharmaceuticals SA Stock Swiss Exchange

Equities

LU1202320294

Pharmaceuticals

End-of-day quote Swiss Exchange
- CHF - Intraday chart for COSMO Pharmaceuticals SA

Financials

Sales 2023 96.72M 103M 94.65M Sales 2024 * 262M 280M 256M Capitalization 1.24B 1.32B 1.21B
Net income 2023 1M 1.07M 979K Net income 2024 * 111M 119M 109M EV / Sales 2023 8.6 x
Net cash position 2023 48.44M 51.83M 47.4M Net cash position 2024 * 110M 118M 108M EV / Sales 2024 * 4.31 x
P/E ratio 2023
771 x
P/E ratio 2024 *
10.6 x
Employees -
Yield 2023
3.65%
Yield 2024 *
2.72%
Free-Float 44.49%
More Fundamentals * Assessed data

Latest transcript on COSMO Pharmaceuticals SA

Managers TitleAgeSince
Chief Executive Officer 61 05-12-31
Director of Finance/CFO 52 16-05-31
Chief Tech/Sci/R&D Officer 54 -
Members of the board TitleAgeSince
Director/Board Member 57 21-05-27
Founder 69 96-12-31
Director/Board Member 64 05-12-31
More insiders
Cosmo Pharmaceuticals N.V. is a pharmaceutical company. The Company is focused on gastrointestinal (GI) diseases and dermatology. Its development pipeline is focused on Bowel Diseases, Colon Infections, and products to reduce the incidence of Colorectal Cancer (CRC) by increasing the detection of cancerous and pre-cancerous lesions during colonoscopy. Products which it has developed include Lialda/Mezavant/Mesavancol and Uceris/Cortiment, for the treatment of ulcerative colitis; GI Genius, which uses artificial intelligence to aid the detection of colorectal polyps during colonoscopy; Eleview, a submucosal injectable composition for use in gastrointestinal endoscopic procedures; Aemcolo for the treatment of travellers’ diarrhoea (TD), Methylene Blue MMX, which is a new diagnostic drug to improve precancerous and cancerous lesion detection during colonoscopy and Winlevi for the treatment of acne. Its therapeutic focus is on the oral and endoscopic treatment of colon diseases.
Calendar
More about the company